ArticleClinical and experimental pediatrics2021
Effects of nasopharyngeal microbiota in respiratory infections and allergies.
Article in Clinical and experimental pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Review
- Impact of rapid maxillary expansion on nasal microbiota in mouth-breathing children: a prospective cohort study.BMC oral health · 2026Article
- Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management.Infectious diseases and therapy · 2026Review
- Nasal Microbiota as a Potential Therapeutic Target for Allergic Rhinitis: An Emerging Perspective.Current pharmaceutical design · 2026Review
- Presence of Dolosigranulum pigrum in the nasopharynx and its relationship with respiratory health status in paediatric population.PloS one · 2026Article
- The neonatal and maternal nasal microbiomes are compositionally diverse and functionally distinct within 24 hours of birth.Frontiers in cellular and infection microbiology · 2026Article
- Nasal-spraying Bacillus spore probiotics for pneumonia in children with respiratory syncytial virus and bacterial co-infections: a randomized clinical trial.Communications medicine · 2025Article
- Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment.Discover oncology · 2025Review
- Respiratory Flora Intervention: A New Strategy for the Prevention and Treatment of Occupationally Related Respiratory Allergy in Healthcare Workers.Microorganisms · 2024Review
- Recent increase in atypical presentations of invasive meningococcal disease in France.BMC infectious diseases · 2024Article
- Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the "Constructing a 'Eubiosis Reinstatement Therapy' for Asthma-CURE" Project.Pulmonary therapy · 2024Review
- Article
- Draft genome sequence of novel Candidatus Ornithobacterium hominis carrying antimicrobial resistance genes in Egypt.BMC microbiology · 2024Article
- Expert consensus on the use of oropharyngeal probiotic Bactoblis in respiratory tract infection and otitis media: available clinical evidence and recommendations for future research.Frontiers in pediatrics · 2024Article
- Bacterial Proteases as Potentially Exploitable Modulators of SARS-CoV-2 Infection: Logic from the Literature, Informatics, and Inspiration from the Dog.Biotech (Basel (Switzerland)) · 2023Article
- Reduced microbial diversity of the nasopharyngeal microbiome in household contacts with latent tuberculosis infection.Scientific reports · 2023Article
- Detection of Main Causative Agents among Young Children Suffering from Epiglottitis in Hilla City, Iraq.Archives of Razi Institute · 2023Article
- Etiology and Epidemiology of Croup before and throughout the COVID-19 Pandemic, 2018-2022, South Korea.Children (Basel, Switzerland) · 2022Article
- Clinical perspectives on nasopharyngeal morphology in humans.Anatomical record (Hoboken, N.J. : 2007) · 2022Article
- A complete guide to human microbiomes: Body niches, transmission, development, dysbiosis, and restoration.Frontiers in systems biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human microbiome, which consists of a collective cluster of commensal, symbiotic, and pathogenic microorganisms living in the human body, plays a key role in host health and immunity. The human nasal cavity harbors commensal bacteria that suppress the colonization of opportunistic pathogens. However, dysbiosis of the nasal microbial community is associated with many diseases, such as acute respiratory infections including otitis media, sinusitis and bronchitis and allergic respiratory diseases including asthma. The nasopharyngeal acquisition of pneumococcus, which exists as a pathobiont in the nasal cavity, is the initial step in virtually all pneumococcal diseases. Although the factors influencing nasal colonization and elimination are not fully understood, the adhesion of opportunistic pathogens to nasopharyngeal mucosa receptors and the eliciting of immune responses in the host are implicated in addition to bacterial microbiota properties and colonization resistance dynamics. Probiotics or synbiotic interventions may show promising and effective roles in the adjunctive treatment of dysbiosis; however, more studies are needed to characterize how these interventions can be applied in clinical practice in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.